_id
69147a13ccc777a4e85d8fab
Ticker
MLYS
Name
Mineralys Therapeutics, Inc. Common Stock
Exchange
NASDAQ
Address
150 N. Radnor Chester Rd., Radnor, PA, United States, 19087
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://mineralystx.com
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Last Close
36.24
Volume
888439
Current Price
33.37
Change
-0.58
Last Updated
2026-01-05T10:37:45.557Z
Image
data:image/webp;base64,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
Ipo Date
2023-02-10T00:00:00.000Z
Market Cap
2826087680
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9942
Sentiment Sources
5
Rating
4.75
Target Price
50.875
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
15000
Gross Profit
-15000
Operating Expenses
41116000
Operating Income
-41131000
Interest Expense
-
Pretax Income
-36932000
Net Income
-36932000
Eps
-0.5231568735152526
Dividends Per Share
-
Shares Outstanding
79139956
Income Tax Expense
-
EBITDA
-36917000
Operating Margin
-
Total Other Income Expense Net
4199000
Cash
217597000
Short Term Investments
376031000
Receivables
-
Inventories
-
Total Current Assets
599796000
Property Plant Equipment
7000
Total Assets
599947000
Payables
1121000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
23520000
Equity
576427000
Bs_currency_symbol
USD
Depreciation
15000
Change In Working Capital
4600000
Cash From Operations
-28872000
Capital Expenditures
0
Cash From Investing
-150507000
Cash From Financing
295188000
Net Change In Cash
115809000
Cf_currency_symbol
USD
PE
-
PB
4.086794335588027
ROE
-6.407055880449736
ROA
-6.155877102477385
FCF
-28872000
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
15000
Quarters > 0 > income Statement > gross Profit
-15000
Quarters > 0 > income Statement > operating Expenses
41116000
Quarters > 0 > income Statement > operating Income
-41131000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-36932000
Quarters > 0 > income Statement > net Income
-36932000
Quarters > 0 > income Statement > eps
-0.5231568735152526
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
70594504
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-36917000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
4199000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
217597000
Quarters > 0 > balance Sheet > short Term Investments
376031000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
599796000
Quarters > 0 > balance Sheet > property Plant Equipment
7000
Quarters > 0 > balance Sheet > total Assets
599947000
Quarters > 0 > balance Sheet > payables
1121000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
23520000
Quarters > 0 > balance Sheet > equity
576427000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-36932000
Quarters > 0 > cash Flow > depreciation
15000
Quarters > 0 > cash Flow > change In Working Capital
4600000
Quarters > 0 > cash Flow > cash From Operations
-28872000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-150507000
Quarters > 0 > cash Flow > cash From Financing
295188000
Quarters > 0 > cash Flow > net Change In Cash
115809000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.5231568735152526
Quarters > 0 > ratios > PB
4.086794335588027
Quarters > 0 > ratios > ROE
-6.407055880449736
Quarters > 0 > ratios > ROA
-6.155877102477385
Quarters > 0 > ratios > FCF
-28872000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
16000
Quarters > 1 > income Statement > gross Profit
-16000
Quarters > 1 > income Statement > operating Expenses
46746000
Quarters > 1 > income Statement > operating Income
-46746000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-43274000
Quarters > 1 > income Statement > net Income
-43274000
Quarters > 1 > income Statement > eps
-0.6611633685425669
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
65451297
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-46730000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
3472000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
101788000
Quarters > 1 > balance Sheet > short Term Investments
223128000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
335269000
Quarters > 1 > balance Sheet > property Plant Equipment
22000
Quarters > 1 > balance Sheet > total Assets
335724000
Quarters > 1 > balance Sheet > payables
3164000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
22173000
Quarters > 1 > balance Sheet > equity
313551000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-43274000
Quarters > 1 > cash Flow > depreciation
16000
Quarters > 1 > cash Flow > change In Working Capital
10765000
Quarters > 1 > cash Flow > cash From Operations
-30169000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-42881000
Quarters > 1 > cash Flow > cash From Financing
9831000
Quarters > 1 > cash Flow > net Change In Cash
-63219000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.6611633685425669
Quarters > 1 > ratios > PB
6.965724175301625
Quarters > 1 > ratios > ROE
-13.801263590293125
Quarters > 1 > ratios > ROA
-12.889754679439063
Quarters > 1 > ratios > FCF
-30169000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
15000
Quarters > 2 > income Statement > gross Profit
-15000
Quarters > 2 > income Statement > operating Expenses
44447000
Quarters > 2 > income Statement > operating Income
-44447000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-42211000
Quarters > 2 > income Statement > net Income
-42211000
Quarters > 2 > income Statement > eps
-0.7939838330212367
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
53163551
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-44432000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2236000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
165007000
Quarters > 2 > balance Sheet > short Term Investments
178019000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
354506000
Quarters > 2 > balance Sheet > property Plant Equipment
38000
Quarters > 2 > balance Sheet > total Assets
354941000
Quarters > 2 > balance Sheet > payables
373000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
13386000
Quarters > 2 > balance Sheet > equity
341555000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-42211000
Quarters > 2 > cash Flow > depreciation
15000
Quarters > 2 > cash Flow > change In Working Capital
-5890000
Quarters > 2 > cash Flow > cash From Operations
-45487000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-92876000
Quarters > 2 > cash Flow > cash From Financing
189279000
Quarters > 2 > cash Flow > net Change In Cash
50916000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.7939838330212367
Quarters > 2 > ratios > PB
5.194090840040403
Quarters > 2 > ratios > ROE
-12.358478136756892
Quarters > 2 > ratios > ROA
-11.892399018428415
Quarters > 2 > ratios > FCF
-45487000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
37
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
34000
Quarters > 3 > income Statement > cost Of Revenue
17000
Quarters > 3 > income Statement > gross Profit
17000
Quarters > 3 > income Statement > operating Expenses
51767000
Quarters > 3 > income Statement > operating Income
-51767000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-48946000
Quarters > 3 > income Statement > net Income
-48946000
Quarters > 3 > income Statement > eps
-0.9797447099070113
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
49957912
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-51752000
Quarters > 3 > income Statement > operating Margin
-152255.88235294117
Quarters > 3 > income Statement > total Other Income Expense Net
2821000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
114091000
Quarters > 3 > balance Sheet > short Term Investments
84096000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
205351000
Quarters > 3 > balance Sheet > property Plant Equipment
53000
Quarters > 3 > balance Sheet > total Assets
205903000
Quarters > 3 > balance Sheet > payables
479000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
14646000
Quarters > 3 > balance Sheet > equity
191257000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-48946000
Quarters > 3 > cash Flow > depreciation
15000
Quarters > 3 > cash Flow > change In Working Capital
-19709000
Quarters > 3 > cash Flow > cash From Operations
-66843000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
83570000
Quarters > 3 > cash Flow > cash From Financing
90000
Quarters > 3 > cash Flow > net Change In Cash
16817000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.9797447099070113
Quarters > 3 > ratios > PB
8.71652030221116
Quarters > 3 > ratios > ROE
-25.591743047313305
Quarters > 3 > ratios > ROA
-23.771387497996628
Quarters > 3 > ratios > FCF
-66843000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-1965.9705882352941
Quarters > 3 > health Score
26
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
43000
Annuals > 0 > income Statement > gross Profit
-43000
Annuals > 0 > income Statement > operating Expenses
192403000
Annuals > 0 > income Statement > operating Income
-192403000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-177810000
Annuals > 0 > income Statement > net Income
-177810000
Annuals > 0 > income Statement > eps
-3.6631798712788135
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
48539795
Annuals > 0 > income Statement > income Tax Expense
-177810000
Annuals > 0 > income Statement > EBITDA
-192360000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
14593000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
114091000
Annuals > 0 > balance Sheet > short Term Investments
84096000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
205351000
Annuals > 0 > balance Sheet > property Plant Equipment
53000
Annuals > 0 > balance Sheet > total Assets
205903000
Annuals > 0 > balance Sheet > payables
479000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
14646000
Annuals > 0 > balance Sheet > equity
191257000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-177810000
Annuals > 0 > cash Flow > depreciation
43000
Annuals > 0 > cash Flow > change In Working Capital
9522000
Annuals > 0 > cash Flow > cash From Operations
-166314000
Annuals > 0 > cash Flow > capital Expenditures
96000
Annuals > 0 > cash Flow > cash From Investing
114959000
Annuals > 0 > cash Flow > cash From Financing
116142000
Annuals > 0 > cash Flow > net Change In Cash
64787000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-3.6631798712788135
Annuals > 0 > ratios > PB
9.062968045352589
Annuals > 0 > ratios > ROE
-92.96914622732763
Annuals > 0 > ratios > ROA
-86.35619684997305
Annuals > 0 > ratios > FCF
-166410000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
26
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
84657000
Annuals > 1 > income Statement > operating Income
-84657000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-71898000
Annuals > 1 > income Statement > net Income
-71898000
Annuals > 1 > income Statement > eps
-1.9867772565098056
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
36188254
Annuals > 1 > income Statement > income Tax Expense
-167895
Annuals > 1 > income Statement > EBITDA
-84657000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
12759000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
49304000
Annuals > 1 > balance Sheet > short Term Investments
187263000
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
249103000
Annuals > 1 > balance Sheet > property Plant Equipment
0
Annuals > 1 > balance Sheet > total Assets
251636000
Annuals > 1 > balance Sheet > payables
601000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
10482000
Annuals > 1 > balance Sheet > equity
241154000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-71898000
Annuals > 1 > cash Flow > depreciation
0
Annuals > 1 > cash Flow > change In Working Capital
-7470000
Annuals > 1 > cash Flow > cash From Operations
-81173000
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
-160472000
Annuals > 1 > cash Flow > cash From Financing
203248000
Annuals > 1 > cash Flow > net Change In Cash
-38397000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-1.9867772565098056
Annuals > 1 > ratios > PB
5.358743999021372
Annuals > 1 > ratios > ROE
-29.814143659238496
Annuals > 1 > ratios > ROA
-28.572223370264986
Annuals > 1 > ratios > FCF
-81173000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
31479000
Annuals > 2 > income Statement > operating Income
-31479000
Annuals > 2 > income Statement > interest Expense
1676000
Annuals > 2 > income Statement > pretax Income
-29799000
Annuals > 2 > income Statement > net Income
-29799000
Annuals > 2 > income Statement > eps
-5.7668459480548435
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
5167296
Annuals > 2 > income Statement > income Tax Expense
-1904485
Annuals > 2 > income Statement > EBITDA
-31479000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
4000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
87701000
Annuals > 2 > balance Sheet > short Term Investments
22409000
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
112811000
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
114442000
Annuals > 2 > balance Sheet > payables
1907000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
166711000
Annuals > 2 > balance Sheet > equity
-52269000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-29799000
Annuals > 2 > cash Flow > depreciation
228485
Annuals > 2 > cash Flow > change In Working Capital
772000
Annuals > 2 > cash Flow > cash From Operations
-29221000
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-21759000
Annuals > 2 > cash Flow > cash From Financing
128019000
Annuals > 2 > cash Flow > net Change In Cash
77039000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-5.7668459480548435
Annuals > 2 > ratios > PB
-3.5302787533719795
Annuals > 2 > ratios > ROE
57.010847730012046
Annuals > 2 > ratios > ROA
-26.038517327554565
Annuals > 2 > ratios > FCF
-29221000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
18725000
Annuals > 3 > income Statement > operating Income
-18725000
Annuals > 3 > income Statement > interest Expense
27000
Annuals > 3 > income Statement > pretax Income
-19408000
Annuals > 3 > income Statement > net Income
-19408000
Annuals > 3 > income Statement > eps
-3.8938375526605014
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
4984286
Annuals > 3 > income Statement > income Tax Expense
27000
Annuals > 3 > income Statement > EBITDA
-19381000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-683000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
10612000
Annuals > 3 > balance Sheet > short Term Investments
0
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
11122000
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
11125000
Annuals > 3 > balance Sheet > payables
763000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
34050000
Annuals > 3 > balance Sheet > equity
-22925000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-19408000
Annuals > 3 > cash Flow > depreciation
18725000
Annuals > 3 > cash Flow > change In Working Capital
4085000
Annuals > 3 > cash Flow > cash From Operations
-14559000
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-21759000
Annuals > 3 > cash Flow > cash From Financing
23812000
Annuals > 3 > cash Flow > net Change In Cash
9253000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-3.8938375526605014
Annuals > 3 > ratios > PB
-7.7639630560523445
Annuals > 3 > ratios > ROE
84.65866957470011
Annuals > 3 > ratios > ROA
-174.45393258426967
Annuals > 3 > ratios > FCF
-14559000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
30
Valuation > metrics > PE
-0.5231568735152526
Valuation > metrics > PB
4.086794335588027
Valuation > final Score
39.13205664411973
Valuation > verdict
36.2% Overvalued
Profitability > metrics > ROE
-6.407055880449736
Profitability > metrics > ROA
-6.157426858465211
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.04080308521287171
Risk > metrics > Interest Coverage
-2742.0666666666666
Risk > final Score
-10908
Risk > verdict
High
Liquidity > metrics > Current Ratio
535.0544157002677
Liquidity > metrics > Quick Ratio
535.0544157002677
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
28.059091599595973
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
6
Prev Risks > 1
-20
Prev Risks > 2
-14
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:13:08.812Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-11
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.52
Earnings History > 0 > eps Estimate
-0.64
Earnings History > 0 > eps Difference
0.12
Earnings History > 0 > surprise Percent
18.75
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-12
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
AfterMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.66
Earnings History > 1 > eps Estimate
-0.74
Earnings History > 1 > eps Difference
0.08
Earnings History > 1 > surprise Percent
10.8108
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-12
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
-0.79
Earnings History > 2 > eps Estimate
-0.98
Earnings History > 2 > eps Difference
0.19
Earnings History > 2 > surprise Percent
19.3878
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-02-12
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
BeforeMarket
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.98
Earnings History > 3 > eps Estimate
-1.08
Earnings History > 3 > eps Difference
0.1
Earnings History > 3 > surprise Percent
9.2593
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-11
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
AfterMarket
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-1.13
Earnings History > 4 > eps Estimate
-0.83
Earnings History > 4 > eps Difference
-0.3
Earnings History > 4 > surprise Percent
-36.1446
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-13
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
AfterMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.83
Earnings History > 5 > eps Estimate
-0.7
Earnings History > 5 > eps Difference
-0.13
Earnings History > 5 > surprise Percent
-18.5714
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-09
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.7
Earnings History > 6 > eps Estimate
-0.67
Earnings History > 6 > eps Difference
-0.03
Earnings History > 6 > surprise Percent
-4.4776
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-03-21
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.61
Earnings History > 7 > eps Estimate
-0.82
Earnings History > 7 > eps Difference
0.21
Earnings History > 7 > surprise Percent
25.6098
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-11-07
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.57
Earnings History > 8 > eps Estimate
-0.76
Earnings History > 8 > eps Difference
0.19
Earnings History > 8 > surprise Percent
25
Earnings History > 9 > period
2023-06-30
Earnings History > 9 > report Date
2023-08-07
Earnings History > 9 > date
2023-06-30
Earnings History > 9 > before After Market
AfterMarket
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-0.31
Earnings History > 9 > eps Estimate
-0.72
Earnings History > 9 > eps Difference
0.41
Earnings History > 9 > surprise Percent
56.9444
Earnings History > 10 > period
2023-03-31
Earnings History > 10 > report Date
2023-05-15
Earnings History > 10 > date
2023-03-31
Earnings History > 10 > before After Market
AfterMarket
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
-0.51
Earnings History > 10 > eps Estimate
-0.89
Earnings History > 10 > eps Difference
0.38
Earnings History > 10 > surprise Percent
42.6966
Earnings History > 11 > period
2022-12-31
Earnings History > 11 > report Date
2023-03-15
Earnings History > 11 > date
2022-12-31
Earnings History > 11 > before After Market
AfterMarket
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-1.74
Earnings History > 11 > eps Estimate
-1.72
Earnings History > 11 > eps Difference
-0.02
Earnings History > 11 > surprise Percent
-1.1628
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ARodman sells Mineralys (MLYS) shares for $13,353 By Investing.com Investing.com Nigeria
Read more →David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
1/21/2026
David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$50.875
Analyst Picks
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Mineralys Therapeutics, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.52
EPS Estimate
-0.64
EPS Difference
0.12
Surprise Percent
18.75%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.